NCT04941781 is a Phase 1 clinical trial of PIPE-307 in Multiple Sclerosis, sponsored by Contineum Therapeutics.

Who is sponsoring NCT04941781?

NCT04941781 is sponsored by Contineum Therapeutics.

What drugs are being tested in NCT04941781?

Interventions in NCT04941781: PIPE-307.

What condition does NCT04941781 study?

NCT04941781 studies Multiple Sclerosis.

Is NCT04941781 still recruiting?

NCT04941781 is currently completed. Last updated 5 October 2022.

Last reviewed 2022-10-05 · How we verify

NCT04941781

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers

Completed Phase 1 Last updated 5 October 2022

What this trial tests

Phase 1 trial testing PIPE-307 in Multiple Sclerosis in 6 participants. Completed in 10 November 2021.

Timeline

1 September 2021

Primary endpoint
10 November 2021

10 November 2021

Quick facts

Lead sponsor	Contineum Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	1 September 2021
Primary completion	10 November 2021
Estimated completion	10 November 2021
Sites	1 location across United Kingdom

Drugs / interventions tested

PIPE-307 — full drug profile →

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

Contineum Therapeutics — full company profile →

Who can join

Adults 25 to 65, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1, single-center, open-label, adaptive-design PET study to investigate the occupancy of brain muscarinic Type 1 receptors (M1AChR) by PIPE-307 in healthy volunteers.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Potential Role for Combined Subtype-Selective Targeting of M<sub>1</sub> and M<sub>3</sub> Muscarinic Receptors in Gastrointestinal and Liver Diseases.
Tolaymat M, Sundel MH, Alizadeh M, Xie G, et al · · 2021 · cited 12× · PMID 34803723 · DOI 10.3389/fphar.2021.786105
Enhancing remyelination in multiple sclerosis via M1 muscarinic acetylcholine receptor.
Chen K, Park E, Abd-Elrahman KS. · · 2025 · cited 8× · PMID 40158341 · DOI 10.1016/j.molpha.2025.100027
The potential of repurposing clemastine to promote remyelination.
Yamazaki R, Ohno N. · · 2025 · cited 5× · PMID 40400770 · DOI 10.3389/fncel.2025.1582902
Translational molecular imaging and drug development in multiple sclerosis.
Tay D, Ahmed H, Dawoud A, Salam M, et al · · 2026 · PMID 41356192 · DOI 10.7150/thno.119559

Verify or expand the search:

Other trials of PIPE-307

Trials testing the same drug.

NCT04725175 — Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect · Phase 1 · completed

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Other Contineum Therapeutics trials

Trials by the same sponsor.

NCT06810245 — Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain · Phase 1 · completed
NCT06683612 — PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF · Phase 1 · completed
NCT06083753 — Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis · Phase 2 · completed
NCT05983939 — Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy · Phase 1 · completed
NCT04725175 — Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04941781 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Contineum Therapeutics
Last refreshed: 5 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04941781.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing